 This study will investigate if antibody production differs between nv AMD patients Groups 1, 3 and 5 and the normal population Group 2, if it differs between ranibizumab responders Group 1 and non-responders to any anti-VEGF treatment Groups 3 and 5, and we will also see how patients with dry AMD Group 4 compare with the nv AMD groups Groups 1, 3, and 5. 